CFDA Says Regulatory Reform Needs Market Push: DIA China Meeting
This article was originally published in PharmAsia News
Executive Summary
China FDA plans to push reforms by looking to markets for ideas and feedback, delegating tasks to provincial branches, procuring third-party services, and considering a drug review fee increase, says CFDA deputy commissioner Yin Li.